Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 3 1

Status

Completed 8Recruiting 7Active not recruiting 6Not yet recruiting 4Terminated 3Withdrawn 2Unknown 2

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Triple Negative Breast Neoplasms 4Ovarian Neoplasms 3Stomach Neoplasms 1Solid Tumor 1Prostatic Neoplasms 1Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Carboplatin 12pembrolizumab 8Paclitaxel 8Cyclophosphamide 8toripalimab 4sacituzumab govitecan 4olaparib 4Epirubicin 4Drug Therapy 4Doxorubicin 4eribulin 3Capecitabine 3130-nm albumin-bound paclitaxel 3trastuzumab deruxtecan 2Radiotherapy 2Injections 2Gemcitabine 2taxane 1poly ICLC 1pirfenidone 1palbociclib 1ivarmacitinib 1inavolisib 1fludarabine 1daratumumab 1camrelizumab 1axatilimab 1anlotinib 1aldesleukin 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Not yet recruiting × Triple Negative Breast Neoplasms × olaparib × Clear all
NCT07486687 2026-03-20

PLANET

The Netherlands Cancer Institute

Phase 3 Not yet recruiting
1,000 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05128734 2025-12-15

Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)

AHS Cancer Control Alberta

Phase 2 Not yet recruiting
40 enrolled
Breast

Triple Negative Breast Neoplasms

NCT07187674 2025-09-23

The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel

Harbin Medical University

Phase NA Not yet recruiting
20 enrolled
Breast

Triple Negative Breast Neoplasms

NCT07005583 2025-06-05

Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
46 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡